SA519402217B1 - مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون - Google Patents
مثبطات إيميدازو بيرازين لكيناز تيروسين بروتونInfo
- Publication number
- SA519402217B1 SA519402217B1 SA519402217A SA519402217A SA519402217B1 SA 519402217 B1 SA519402217 B1 SA 519402217B1 SA 519402217 A SA519402217 A SA 519402217A SA 519402217 A SA519402217 A SA 519402217A SA 519402217 B1 SA519402217 B1 SA 519402217B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- imidazopyrazine
- bruton
- inhibitors
- tyrosine kinase
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
يتعلق الاختراع الحالي في بعض التجسيدات، بالمركبات بالصيغة (I) و(II) أو ملح مقبول صيدلانياً منها، أو بتركيبات صيدلانية pharmaceutical compositions تشتمل على هذه المركبات واستخدامها في العلاج. بالتحديد، في بعض التجسيدات، يتعلق الاختراع الحالي بالمركبات بالصيغة (I) و(II)، تركيبات صيدلانية منها، واستخدام المركبات والتركيبات الصيدلانية في معالجة اضطراب فرط التكاثر hyperproliferative disorder، اضطراب التهابي inflammatory disorder، اضطراب مناعي immune disorder، أو اضطراب مناعة ذاتية autoimmune disorder. شكل1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437633P | 2016-12-21 | 2016-12-21 | |
| US201762569028P | 2017-10-06 | 2017-10-06 | |
| PCT/IB2017/058319 WO2018116259A1 (en) | 2016-12-21 | 2017-12-21 | Imidazopyrazine inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519402217B1 true SA519402217B1 (ar) | 2022-04-19 |
Family
ID=60972291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519402217A SA519402217B1 (ar) | 2016-12-21 | 2019-06-19 | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10858364B2 (ar) |
| EP (1) | EP3558968B1 (ar) |
| JP (1) | JP7022131B2 (ar) |
| KR (1) | KR102559851B1 (ar) |
| CN (1) | CN110291080B (ar) |
| AU (1) | AU2017383236B2 (ar) |
| BR (1) | BR112019012604A2 (ar) |
| CA (1) | CA3046578A1 (ar) |
| CL (1) | CL2019001674A1 (ar) |
| ES (1) | ES2856248T3 (ar) |
| IL (1) | IL267374B (ar) |
| MX (1) | MX2019007156A (ar) |
| SA (1) | SA519402217B1 (ar) |
| WO (1) | WO2018116259A1 (ar) |
| ZA (1) | ZA201903932B (ar) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| SG11201805300QA (en) | 2015-12-22 | 2018-07-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| ES2934230T3 (es) | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
| US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| CN112752756A (zh) | 2018-05-11 | 2021-05-04 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| ES2966457T3 (es) | 2018-06-18 | 2024-04-22 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| AU2020357514A1 (en) | 2019-09-30 | 2022-04-07 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| WO2021096849A1 (en) | 2019-11-11 | 2021-05-20 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| CN114807038B (zh) * | 2022-02-11 | 2023-11-10 | 四川大学华西第二医院 | 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0622054B8 (pt) * | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| EP2419429B1 (en) * | 2009-04-16 | 2014-03-26 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines as inhibitors of protein kinases |
| SI3689878T1 (sl) * | 2011-07-19 | 2021-12-31 | Merck Sharp & Dohme B.V. | 4-imidazopiridazin-1-il-benzamidi in 4-imidazotriazin-1-il-benzamidi kot Btk-zaviralci |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| EP2734523A1 (en) | 2011-07-19 | 2014-05-28 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| CA2931431A1 (en) * | 2013-12-05 | 2015-06-11 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
| WO2015110923A2 (en) | 2014-01-21 | 2015-07-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor |
| WO2016024227A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment |
| WO2016106623A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
| WO2016106627A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| US20180305348A1 (en) * | 2015-06-02 | 2018-10-25 | Pharmacyclics Llc | Inhibitors of brutons tyrosine kinase |
-
2017
- 2017-12-21 JP JP2019533229A patent/JP7022131B2/ja active Active
- 2017-12-21 CN CN201780086892.3A patent/CN110291080B/zh active Active
- 2017-12-21 EP EP17829328.8A patent/EP3558968B1/en active Active
- 2017-12-21 WO PCT/IB2017/058319 patent/WO2018116259A1/en unknown
- 2017-12-21 CA CA3046578A patent/CA3046578A1/en active Pending
- 2017-12-21 ES ES17829328T patent/ES2856248T3/es active Active
- 2017-12-21 KR KR1020197020718A patent/KR102559851B1/ko active IP Right Grant
- 2017-12-21 MX MX2019007156A patent/MX2019007156A/es unknown
- 2017-12-21 AU AU2017383236A patent/AU2017383236B2/en active Active
- 2017-12-21 BR BR112019012604A patent/BR112019012604A2/pt active Search and Examination
- 2017-12-21 US US16/448,056 patent/US10858364B2/en active Active
-
2019
- 2019-06-16 IL IL267374A patent/IL267374B/en unknown
- 2019-06-18 CL CL2019001674A patent/CL2019001674A1/es unknown
- 2019-06-18 ZA ZA2019/03932A patent/ZA201903932B/en unknown
- 2019-06-19 SA SA519402217A patent/SA519402217B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017383236B2 (en) | 2022-02-10 |
| JP2020514264A (ja) | 2020-05-21 |
| JP7022131B2 (ja) | 2022-02-17 |
| US10858364B2 (en) | 2020-12-08 |
| AU2017383236A1 (en) | 2019-06-27 |
| US20190345164A1 (en) | 2019-11-14 |
| CL2019001674A1 (es) | 2019-11-08 |
| EP3558968B1 (en) | 2021-02-03 |
| CA3046578A1 (en) | 2018-06-28 |
| KR102559851B1 (ko) | 2023-07-25 |
| EP3558968A1 (en) | 2019-10-30 |
| ES2856248T3 (es) | 2021-09-27 |
| MX2019007156A (es) | 2019-09-05 |
| IL267374A (en) | 2019-08-29 |
| ZA201903932B (en) | 2021-01-27 |
| CN110291080B (zh) | 2022-07-08 |
| WO2018116259A1 (en) | 2018-06-28 |
| IL267374B (en) | 2021-07-29 |
| CN110291080A (zh) | 2019-09-27 |
| BR112019012604A2 (pt) | 2019-11-26 |
| KR20190095403A (ko) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201891229A1 (ru) | Eif4a-ингибирующие соединения и связанные с ними способы | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| EA201790951A1 (ru) | Производные гидроксиалкилзамещенного фенилтриазола и их применение | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| TW201613577A (en) | Pharmaceutical combinations | |
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| PH12019501999A1 (en) | Pyrazole derivatives as bromodomain inhibitors | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2020000402A (es) | Nuevos derivados de xantina sustituidos. | |
| WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
| MX2021015333A (es) | Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| EA201991456A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы брутона |